Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials

Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials

Background: About one-tenth of patients with difficult-to-treat chronic rhinosinusitis with nasal polyps (CRSwNP) have comorbid non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD). Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)-4/IL-...

Full description

Bibliographic Details
Main Authors: Amin, N. (Author), Bachert, C. (Author), Canonica, G.W (Author), Daizadeh, N. (Author), Han, J. (Author), Laidlaw, T.M (Author), Laws, E. (Author), Li, Y. (Author), Mannent, L.P (Author), Maspero, J.F (Author), Mullol, J. (Author), Ortiz, B. (Author), Picado, C. (Author), Ruddy, M. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2022
Subjects:
chronic rhinosinusitis with nasal polyps
dupilumab
IL-13
IL-4
non-steroidal anti-inflammatory drug-exacerbated respiratory disease
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items